title: Safety profile of six months lansoprozole treatment in children.
authors.forename: Makbule
authors.initials: M
authors.lastname: Eren
authors.forename: Selda Hekim
authors.initials: SH
authors.lastname: Yıldırım
authors.forename: Ilknur Ak
authors.initials: IA
authors.lastname: Sivrikoz
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D000293:Adolescent; D015519:Bone Density; D002118:Calcium / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006454:Hemoglobins; D006801:Humans; D007501:Iron / Q000097:blood; D064747:Lansoprazole; D008297:Male; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D013997:Time Factors; D014805:Vitamin B 12 / Q000097:blood
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D006454:Hemoglobins; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D007501:Iron; D014805:Vitamin B 12; D002118:Calcium